IVFNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INVO Fertility, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.60+0.04 (+7.78%)
Close on Oct 19, 2026
- Market cap
- $1.56M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
99.6%+8.1 pts over 5 years
Operating margin
-105.8%+425.9 pts over 5 years
Net margin
-340.9%+463.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +4.7% | +102.6% | +45.8% | +89.1% | |
| Gross profit | +4.5% | +140.3% | +48.3% | +111.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 50.7% | -822.6% | -235.5% | |
| Return on assets | -490.6% | -131.0% | -70.4% | |
| Current ratio | 0.05 | 4.61 | 0.27 | |
| Debt to equity | -0.03 | – | 0.28 | |
| Net debt to EBITDA | 0.01× | – | 0.01× | |
| Interest coverage | -152.5× | -1.9× | -5.6× | |
| Inventory turnover | 0.2× | 0.5× | 0.1× | |
| Capex to revenue | 30.8% | 4.7% | 0.6% | |
| Diluted shares | 0M | 0M | 0M |
Where the cash went
Fiscal 2021 to 2025, five years combined
INVO Fertility generated $27.38M from operations and spent $1.10M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$27.38M
Used
$1.10M
Capital expenditure$1.10M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-340.9%
×Asset turnover0.21×
×Equity multiplier3.35×
=Return on equity, FY2025-235.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -340.9% | 0.21× | 3.35× | -235.5% |
| FY2024 | -141.7% | 0.20× | 4.79× | -137.4% |
| FY2023 | -266.0% | 0.27× | -262.02× | 18952.5% |
| FY2022 | -1324.8% | 0.12× | 2.16× | -344.0% |
| FY2021 | -160.0% | 0.40× | 1.60× | -102.0% |
| FY2020 | -804.7% | 0.16× | 6.28× | -822.6% |
| FY2019 | -146.4% | 1.15× | -0.40× | 67.3% |
| FY2018 | -622.2% | 0.95× | -0.14× | 79.7% |
| FY2017 | -248.9% | 1.02× | -0.06× | 14.6% |
| FY2016 | -4173.3% | 0.12× | -0.10× | 50.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$23.32M
- Cash generatingOperating cash flow above zero-$7.01M
- Return on assets improvedROA up on the prior year-50.0% → -50.6%
- Earnings backed by cashOperating cash flow above net income-$7.01M vs -$23.32M
- Less leverageLong-term debt to assets fell2.4% → 3.7%
- Better liquidityCurrent ratio rose0.07 → 0.27
- No dilutionShare count did not rise0M → 0M
- Gross margin improvedGross margin up on the prior year99.81% → 99.55%
- More efficientAsset turnover rose0.35 → 0.15